Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
Victoria M Addis, Eydie Miller-Ellis Division of Glaucoma, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USAAbstract: Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glauc...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2018
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c9383bc0ee124c8e94cd9995197c5860 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|